Vidac Pharma Holding PLC. Stock Analysis T9G.SG

Vidac Pharma Holding Plc operates as a clinical stage bio pharmaceutical company. The firm is focused on discovering and developing medicines for oncologic and onco-dermatologic diseases. The company develops therapeutic candidates designed to modify the hyper-glycolytic tumor microenvironment by targeting the overexpression and mislocalization of the Hexokinase-2 (HK2) metabolic checkpoint in cancer cells, with the aim of renormalizing cellular metabolism and selectively inducing programmed cell death without affecting surrounding normal tissue. Its pipeline includes VDA-1102 - Actinic Keratosis (AK), VDA-1102 - Cutaneous T-Cell Lymphoma (CTCL), and VDA-1275-Solid tumors. VDA-1102 - Actinic Keratosis (AK) is a topical small-molecule candidate designed to target abnormal metabolic processes in malignant cutaneous cells. The VDA-1102 - Cutaneous T-Cell Lymphoma (CTCL) is focused on topical ointment in patients with early-stage CTCL (mycosis fungoides).